Company intelligence / Profile preview

Shanghai Xianxiang Medical Technology

Shanghai, Shanghai Shi, China

Ownership: Private
Development stage: Other

Overview

Shanghai Xianxiang Medical Technology is actively advancing multiple small molecule and antibody-based programs in oncology, neurology, autoimmune diseases, and anti-infective treatments. The company has presented Phase 1 clinical data on a PRMT5 inhibitor (SCR-6920) in advanced tumors, showing no dose-limiting toxicities in 25 patients and dose-dependent plasma biomarker response. Several trispecific and ADC programs are also in early clinical phases.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibody-drug conjugateTrispecific T-cell engager
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Xianxiang Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Xianxiang Medical Technology.

Explore the full profile